floxuridine has been researched along with Urinary Bladder Neoplasms in 20 studies
Floxuridine: An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
floxuridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-fluorouracil as the nucleobase; used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
Urinary Bladder Neoplasms: Tumors or cancer of the URINARY BLADDER.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A total of 112 patients with pTa or pT1 bladder cancer were eligible for the analysis and were allocated to either an adjuvant group (TURBT+5'-DFUR; n = 47; initial 23 months) or a control group (TURBT alone; n = 65, final 23 months)." | 6.71 | Novel prophylactic effect of doxifluridine in superficial bladder cancer. ( Aoki, A; Baba, Y; Jojima, K; Matsuyama, H; Naito, K; Shimabukuro, T; Suga, A; Suyama, K; Uchiyama, K; Yamamoto, N, 2004) |
| "Thymosin is a glycoprotein extract obtained from the calf thymus and is a potent immunopotentiating preparation." | 5.30 | Augmentation of antitumor activity of 5'-deoxy-5-fluorouridine by thymosin fraction 5 in mouse bladder cancer cells in vitro and in vivo. ( Ikemoto, S; Kishimoto, T; Sugimura, K; Wada, S; Yamamoto, K; Yasumoto, R, 1999) |
| " 5-Fluorouracil (5-FU) was effective against only one bladder cancer xenograft among 6 cancer xenografts tested." | 3.68 | [Comparative studies on the antitumor activity of fluorinated pyrimidine derivatives against human bladder, cervical and ovarian cancer xenografts in nude mice]. ( Adachi, S; Akaza, H; Ishitsuka, H; Kanazawa, K; Miwa, M; Nitta, K; Sekiguchi, F; Tokita, H, 1991) |
| "Iododeoxyuridine (IdUrd) potentiated the lethal but not the growth inhibitory properties of fluorouracil (FUra) and fluorodeoxyuridine (FdUrd) in human bladder cancer cells (T24)." | 3.67 | Modulation of 5-iodo-2'-deoxyuridine metabolism and cytotoxicity in human bladder cancer cells by fluoropyrimidines. ( Benson, AB; Cummings, KB; Fischer, PH; Trump, DL, 1985) |
| "A total of 112 patients with pTa or pT1 bladder cancer were eligible for the analysis and were allocated to either an adjuvant group (TURBT+5'-DFUR; n = 47; initial 23 months) or a control group (TURBT alone; n = 65, final 23 months)." | 2.71 | Novel prophylactic effect of doxifluridine in superficial bladder cancer. ( Aoki, A; Baba, Y; Jojima, K; Matsuyama, H; Naito, K; Shimabukuro, T; Suga, A; Suyama, K; Uchiyama, K; Yamamoto, N, 2004) |
| "However, in bladder cancer, response rates have only been reported in Phase II clinical trials." | 2.69 | [5'-DFUR chemoprophylaxis in superficial bladder cancer. Kanagawa Urology 5'-DFUR Study Group]. ( Chiba, K; Ebato, T; Fukuda, M; Fukuoka, H; Fukushima, S; Hirokawa, M; Hosaka, M; Ikeda, I; Kanno, H; Kitami, K; Kondo, I; Kubota, Y; Masuda, M; Miura, T; Miyai, K; Moriyama, M; Noguchi, K; Noguchi, S; Sasaki, K; Sato, K; Senga, Y, 2000) |
| "Therapy of metastatic bladder cancer with doxorubicin-cisplatin was made more tolerable by this same circadian approach resulting in a 57% objective response rate." | 2.41 | Circadian chemotherapy for gynecological and genitourinary cancers. ( Hrushesky, WJ; Kobayashi, M; Wood, PA, 2002) |
| "Thymidine kinase is a key enzyme responsible for the activation of several anticancer and antiviral drugs." | 2.39 | Modulation of thymidine kinase activity: a biochemical strategy to enhance the activation of antineoplastic drugs. ( Vázquez-Padua, MA, 1994) |
| "Gemcitabine was rapidly eliminated from plasma even in patients with renal dysfunction." | 1.35 | Measurement of plasma concentration of gemcitabine and its metabolite dFdU in hemodialysis patients with advanced urothelial cancer. ( Hirobe, M; Itoh, T; Kunishima, Y; Masumori, N; Takayanagi, A; Takeuchi, M; Tsukamoto, T, 2008) |
| "The mean activity in 37 bladder cancers and in 8 samples of normal bladder epithelial tissue was 108." | 1.30 | Thymidine phosphorylase activity in human bladder cancer: difference between superficial and invasive cancer. ( Hosaka, M; Kubota, Y; Matsuzaki, J; Miura, T; Moriyama, M; Noguchi, S; Takebayashi, S, 1997) |
| "Human solid tumor histocultures represent a clinically relevant experimental system for pharmacodynamic study." | 1.30 | Regional heterogeneity and pharmacodynamics in human solid tumor histoculture. ( Au, JL; Weaver, JR; Wientjes, MG, 1999) |
| "Thymosin is a glycoprotein extract obtained from the calf thymus and is a potent immunopotentiating preparation." | 1.30 | Augmentation of antitumor activity of 5'-deoxy-5-fluorouridine by thymosin fraction 5 in mouse bladder cancer cells in vitro and in vivo. ( Ikemoto, S; Kishimoto, T; Sugimura, K; Wada, S; Yamamoto, K; Yasumoto, R, 1999) |
| "Forty-one patients with bladder cancer and 12 patients with prostatic cancer were evaluated." | 1.28 | [Phase II study of 5'-DFUR treatment of the bladder and prostatic cancer]. ( Akebi, N; Josen, T; Kobashi, K; Matsumura, Y; Nanba, K; Nasu, Y; Ochi, J; Ohmori, H; Saika, T; Tanahashi, T, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (25.00) | 18.7374 |
| 1990's | 7 (35.00) | 18.2507 |
| 2000's | 8 (40.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nagata, Y | 1 |
| Masuda, A | 1 |
| Wang, H | 1 |
| Li, H | 1 |
| Zang, M | 1 |
| Xu, F | 1 |
| Li, G | 1 |
| Yan, CY | 1 |
| Wen, DG | 1 |
| Ding, Q | 1 |
| Zhang, YF | 1 |
| Matsuyama, H | 1 |
| Baba, Y | 1 |
| Shimabukuro, T | 1 |
| Uchiyama, K | 1 |
| Aoki, A | 1 |
| Suga, A | 1 |
| Jojima, K | 1 |
| Suyama, K | 1 |
| Yamamoto, N | 1 |
| Naito, K | 1 |
| Masumori, N | 1 |
| Kunishima, Y | 1 |
| Hirobe, M | 1 |
| Takeuchi, M | 1 |
| Takayanagi, A | 1 |
| Tsukamoto, T | 1 |
| Itoh, T | 1 |
| Kawamura, H | 1 |
| Hashimoto, Y | 1 |
| Oberfield, RA | 1 |
| Vázquez-Padua, MA | 2 |
| Kubota, Y | 3 |
| Miura, T | 3 |
| Moriyama, M | 3 |
| Noguchi, S | 2 |
| Matsuzaki, J | 1 |
| Takebayashi, S | 1 |
| Hosaka, M | 3 |
| Weaver, JR | 1 |
| Wientjes, MG | 1 |
| Au, JL | 1 |
| Ikemoto, S | 1 |
| Sugimura, K | 1 |
| Wada, S | 1 |
| Yasumoto, R | 1 |
| Yamamoto, K | 1 |
| Kishimoto, T | 1 |
| Soga, H | 1 |
| Hayashida, H | 1 |
| Yoshiki, T | 1 |
| Higuchi, K | 1 |
| Okada, Y | 1 |
| Masuda, M | 1 |
| Noguchi, K | 1 |
| Sasaki, K | 1 |
| Ikeda, I | 1 |
| Kondo, I | 2 |
| Senga, Y | 1 |
| Fukushima, S | 2 |
| Ebato, T | 1 |
| Fukuda, M | 1 |
| Kitami, K | 1 |
| Fukuoka, H | 2 |
| Sato, K | 1 |
| Hirokawa, M | 1 |
| Chiba, K | 1 |
| Kanno, H | 1 |
| Miyai, K | 2 |
| Kobayashi, M | 1 |
| Wood, PA | 1 |
| Hrushesky, WJ | 1 |
| Carter, SK | 1 |
| Wasserman, TH | 1 |
| Miwa, M | 1 |
| Sekiguchi, F | 1 |
| Akaza, H | 1 |
| Tokita, H | 1 |
| Nitta, K | 1 |
| Adachi, S | 1 |
| Kanazawa, K | 1 |
| Ishitsuka, H | 1 |
| Shuin, T | 1 |
| Kinoshita, Y | 1 |
| Ohmori, H | 1 |
| Matsumura, Y | 1 |
| Ochi, J | 1 |
| Kobashi, K | 1 |
| Akebi, N | 1 |
| Saika, T | 1 |
| Nanba, K | 1 |
| Tanahashi, T | 1 |
| Josen, T | 1 |
| Nasu, Y | 1 |
| Risueno, C | 1 |
| Fischer, PH | 2 |
| Benson, AB | 1 |
| Trump, DL | 1 |
| Cummings, KB | 1 |
2 reviews available for floxuridine and Urinary Bladder Neoplasms
| Article | Year |
|---|---|
Modulation of thymidine kinase activity: a biochemical strategy to enhance the activation of antineoplastic drugs.
Topics: Animals; Antineoplastic Agents; Antiviral Agents; Biotransformation; Chlorocebus aethiops; DNA Damag | 1994 |
Circadian chemotherapy for gynecological and genitourinary cancers.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Cycle; Chronotherapy; Circadian Rhythm; | 2002 |
3 trials available for floxuridine and Urinary Bladder Neoplasms
| Article | Year |
|---|---|
[Prevention and treatment of bladder tumors recurrence with furtulon].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2000 |
Novel prophylactic effect of doxifluridine in superficial bladder cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Carcinoma, Transitional Cell; Cystectomy; Dose | 2004 |
[5'-DFUR chemoprophylaxis in superficial bladder cancer. Kanagawa Urology 5'-DFUR Study Group].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Female; Flo | 2000 |
15 other studies available for floxuridine and Urinary Bladder Neoplasms
| Article | Year |
|---|---|
Bladder tumor associated with phenacetin abuse: a case report and a review of the literature.
Topics: Aged, 80 and over; Analgesics, Non-Narcotic; Antineoplastic Combined Chemotherapy Protocols; Doxorub | 2007 |
[Enhancement effect of interferon gamma on the sensitivity of RT4 bladder cancer cells to 5'-deoxy-5-fluorouridine,and 5-fluorouracil through up-regulation of PD-ECGF/TP].
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Synergism; Floxuridine; Fluorouracil; Humans; Interfer | 2004 |
Measurement of plasma concentration of gemcitabine and its metabolite dFdU in hemodialysis patients with advanced urothelial cancer.
Topics: Antimetabolites, Antineoplastic; Area Under Curve; Bone Neoplasms; Cystectomy; Deoxycytidine; Fatal | 2008 |
Inhibitory effect of 5-halogenated deoxyuridines on in vitro keratinization of a transformed rat urinary bladder epithelial cell line.
Topics: Animals; Binding, Competitive; Bromodeoxyuridine; Cell Line; Cell Transformation, Neoplastic; DNA Re | 1981 |
Intra-arterial infusion in tumors of the pelvis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality T | 1983 |
Thymidine phosphorylase activity in human bladder cancer: difference between superficial and invasive cancer.
Topics: Epithelial Cells; Floxuridine; Fluorouracil; Humans; Kinetics; Neoplasm Invasiveness; Neoplasm Stagi | 1997 |
Regional heterogeneity and pharmacodynamics in human solid tumor histoculture.
Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Cell Division; Culture Techniques; Drug Screeni | 1999 |
Augmentation of antitumor activity of 5'-deoxy-5-fluorouridine by thymosin fraction 5 in mouse bladder cancer cells in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Drug Screening Assays, Antit | 1999 |
[Case report of a patient with invading bladder cancer and lymph node swelling which decreased following 5'-DFUR treatment].
Topics: Aged; Antineoplastic Agents; Child, Preschool; Floxuridine; Humans; Lymph Nodes; Lymphatic Metastasi | 2000 |
The chemotherapy of urologic cancer.
Topics: Adenocarcinoma; Adult; Aged; Alkylating Agents; Antineoplastic Agents; Doxorubicin; Drug Therapy, Co | 1975 |
[Comparative studies on the antitumor activity of fluorinated pyrimidine derivatives against human bladder, cervical and ovarian cancer xenografts in nude mice].
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Female; Floxuridine; | 1991 |
[Phase II study of 5'-DFUR (Furtulon) capsule for bladder cancer].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Agents; Carcinoma, Squamous | 1991 |
[Phase II study of 5'-DFUR treatment of the bladder and prostatic cancer].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Agents; Diarrhea; Dru | 1991 |
Regulation of the activation of fluorodeoxyuridine by substrate competition and feedback inhibition in 647V cells.
Topics: Cell Line; Floxuridine; Humans; Models, Biological; Phosphorylation; Thymidine Kinase; Thymine Nucle | 1989 |
Modulation of 5-iodo-2'-deoxyuridine metabolism and cytotoxicity in human bladder cancer cells by fluoropyrimidines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line; Cell Survival; DNA; Floxuridine; Fluorour | 1985 |